The incidence and clinical significance of antibodies to interferon-a in patients with solid tumors

Biotherapy

Volumn 10, Issue 1, 1997, Pages 1-5

  Öberg, Kjell ^a,b   Alm, Gunnar ^a  

^a Unit University   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

Antibodies; Carcinoid tumor; Human leukocyte interferon; Interferon 2a and 2b; Lymphoblastoid interferon; Renal cell carcinoma

Indexed keywords

ALPHAN1 INTERFERON; DRUG ANTIBODY; INTERFERON ANTIBODY; NEUTRALIZING ANTIBODY; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON;

ANTIBODY PRODUCTION; DRUG EFFICACY; DRUG RESPONSE; HUMAN; IMMUNOASSAY; IMMUNOGENICITY; PRIORITY JOURNAL; SHORT SURVEY; SOLID TUMOR;

EID: 0030877825     PISSN: 0921299X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02678211     Document Type: Short Survey

References (22)

1. Diaz MO. The human type I Interferon cluster. Semin Virol 1995; 6: 143-149.
2. Allen G, Diaz MO. Nomenclature of the human interferon proteins. J Interferon Cytkine Res 1996; 16: 181-184.
3. Henco K, Brosious J, Fujisawa A, et al. Structural relationship of human interferon alpha genes and pseudogenes. J Mol Biol 1985; 185: 227-260.
4. Bacon BR, Farrell G, Benhamou JP, et al. Lymphoblastoid interferon improves long term response to a sic month course of treatment when compared with recombinant interferon alfa 2b: results of an international trial. AASLD abstracts, Hepatology 1995; 22: 152A.
5. Gewert DR, Sharp NA, Barber KA, Cooper H, Tucker D, Lewis AP, Thursz M, Crowe JS. Detection of rare allelic variants of
6. the interferon-α2 gene in human genomic DNA. J Interferon Res 1995; 15:403-406.
7. Hosoi H, Imai M, Yamanaka M. The interferon-α2b gene in Japanese patients with chronic viral hepatitis who developed antibodies after treatment with recombinant interferon-α2a. J Gastroenterol Hepatol 1992; 7:411.
8. Lee N, Ni D, Brissette R, Chou M, Hussain M, Gill DS, Liao MJ, Testa D. Interferon-alpha 2 variants in the human genome. S Interferon Res 1995; 15: 341-349.
9. Strander H, Öberg K. Clinical use of interferons: Solid tumors: In Interferon Principles and Medical Applications: Eds: Barons S, Coppenhaver D.H, Dianzani F, Fleischmann W.R Jr, Hughes T.K Jr, Klimpel G.R, Niesel D.W, Stanton G.J, Tyring S.K: The University of Texas Medical Branch at Galveston (UTMB) 1992 pp 533-562.
10. Itri LM, Campion M, Dennin RA, Palleroni AV, Guttermann JU, Groopman JE, et al. Incidence and clinical significance of neutralizing antibodies in patients receiving recombinant interferon alfa-2a by intramuscular injection. Cancer 1987; 59: 668γ4.
11. Speigel RJ, Spicehandler JR, Jacobs SL, Oden EM. Low incidence of serum neutralizing factors in patients receiving recombianant alfa-2b interferon (Intron A). Am J Med 1986; 80: 223-228.
12. Figlin RA, Itri LM, Anti-interferon antibodies: a perspective. Semin Hematol 1988; 25 (3 suppl): 9-15.
13. Öberg K, Alm G, Magnusson A, Lundqvist G, Theodorsson E, Wide L, et al. Treatment of malignant carcinoid tumors with recombinant interferon-α2b (Intron A): development of neutralizing interferon antibodies and possible loss of antitumor activity. J Natl Cancer Inst 1989; 81: 531-535.
14. Öberg K. Autoimmunity and antibodies to interferons in patients with carcinoid tumours - clinical consequences. J Interferon Res 1994; 14: 215-216.
15. Antonelli G, Currenti M, Turriziani O, Dianzani F. Neutralising antibodies t interferon-a: relative frequency in patients treated with different interferon preparations. J Infect Dis 1991; 163: 882-885.
16. Rönnblom LE, Tiensuu Janson E, Perers A, Öberg KE, Aim GV. Characterization of anti-interferon-a antibodies appearing during recombinant interferon-α2a treatment. Clin Exp Immunol 1992; 89: 330-335.
17. Kawade Y. Quantitation of neutralizing of interferon by antibody; Methods inEnzymology 1986; 119: 558-573.
18. Brand CM, Leadbeater L, Bellati G, Marotta F, Ideo G. Antibodies developing against a single recombinant interferon protein may neutralize many other interferon-alpha subtypes. J Interferon Res 1993 Apr; 13(2): 121-125.
19. Quesada JR, Rios A, Swanson D, Trown P, Guttermann JU. Antitumor activity of recombinant-derived interferon alpha in metastatic renal cell carcinoma. J Clin Oncol 1985; 3: 15221528.
20. Figlin RA, deKernion JB, Mukamel E, Palleroni AV, Itri LM, Sarna GP. Recombinant interferon alfa-2a in metastatic renal cell carcinoma: assessment of antitumor activity and antiinterferon antibody formation. J Clin Oncol 1988; 6: 16041610.
21. Prümmer O. Interferon-alpha antibodies in patients with renal cell carcinoma treated with recombinant interferon-α-2a in an adjuvant multicenter trial. Cancer 1993; 71: 1828-1834.
22. Steis RG, Smith JW II, Urba W, Venzon DJ, Longo DL, Barney R, et al. Loss of interferon antibodies during prolonged continuous of interferon-α2a therapy in hairy cell leukemia. Blood 1991; 77: 792γ98.